BR0113625A - Exemestano como agente de quimioprevenção - Google Patents

Exemestano como agente de quimioprevenção

Info

Publication number
BR0113625A
BR0113625A BR0113625-9A BR0113625A BR0113625A BR 0113625 A BR0113625 A BR 0113625A BR 0113625 A BR0113625 A BR 0113625A BR 0113625 A BR0113625 A BR 0113625A
Authority
BR
Brazil
Prior art keywords
exemestane
chemoprevention agent
chemoprevention
agent
exemestan
Prior art date
Application number
BR0113625-9A
Other languages
English (en)
Inventor
Enrico Di Salle
Lorena Muggetti
Alessandro Martini
Giorgio Massimini
Gabriela Piscitelli
Dinesh Purandare
Original Assignee
Pharmacia Italia Spa
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa, Upjohn Co filed Critical Pharmacia Italia Spa
Publication of BR0113625A publication Critical patent/BR0113625A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Abstract

"EXEMESTANO COMO AGENTE DE QUIMIOPREVENçãO". A presente invenção refere-se ao uso de exemestano inibidor de aromatase, ainda que só ou em combinação com outros agentes terapêuticos, na quimioprevenção de câncer estrógeno dependente em mamíferos, incluindo humanos, em risco aumentado da doença.
BR0113625-9A 2000-09-08 2001-08-31 Exemestano como agente de quimioprevenção BR0113625A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65805200A 2000-09-08 2000-09-08
PCT/EP2001/010172 WO2002020020A1 (en) 2000-09-08 2001-08-31 Exemestane as chemopreventing agent

Publications (1)

Publication Number Publication Date
BR0113625A true BR0113625A (pt) 2003-07-22

Family

ID=24639711

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113625-9A BR0113625A (pt) 2000-09-08 2001-08-31 Exemestano como agente de quimioprevenção

Country Status (15)

Country Link
US (1) US20040024044A1 (pt)
EP (1) EP1317270A1 (pt)
JP (1) JP2004508334A (pt)
KR (1) KR20030043955A (pt)
CN (1) CN1729002A (pt)
AR (1) AR034150A1 (pt)
AU (2) AU8986501A (pt)
BR (1) BR0113625A (pt)
CA (1) CA2419590A1 (pt)
MX (1) MXPA03001983A (pt)
MY (1) MY137766A (pt)
NZ (1) NZ524104A (pt)
PE (1) PE20020348A1 (pt)
WO (1) WO2002020020A1 (pt)
ZA (1) ZA200301309B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
GB0017635D0 (en) * 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
US6903121B1 (en) 2000-08-17 2005-06-07 Allergan, Inc. Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
BR0116575A (pt) * 2001-01-09 2004-01-06 Merck Patent Gmbh Terapia combinada que usa inibidores de tirosina cinase receptora e inibidores de angiogênese
MXPA03006607A (es) * 2001-01-26 2003-09-22 Upjohn Co Metodo combinado para tratar trastornos dependientes de hormonas.
DE10154464B4 (de) * 2001-11-08 2005-10-20 Max Delbrueck Centrum Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes Taxol
ES2279441T3 (es) 2003-09-19 2007-08-16 Astrazeneca Ab Derivados de quinazolina.
AU2006213659A1 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting HER2 shedding with matrix metalloprotease antagonists
CA2605796A1 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
CA2628747C (en) * 2005-11-22 2014-01-21 Incyte Corporation Combinations of hormone therapy agents and metalloprotease inhibitors for the treatment of cancer
TW200800177A (en) * 2006-02-14 2008-01-01 Wyeth Corp Aqueous pharmaceutical formulations of ERβ selective ligands
CN101410012A (zh) * 2006-03-28 2009-04-15 杰佛林制药公司 低剂量的非甾体抗炎药和β-环糊精的制剂
WO2007112272A2 (en) * 2006-03-28 2007-10-04 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
CA2649620A1 (en) * 2006-04-24 2007-11-01 Panacea Biotec Ltd. Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof
CA2700664A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and aromatase inhibitors or combinations of cox-2 inhibitors and estrogen receptor antagonists
CN101468023B (zh) * 2007-12-26 2011-02-02 上海复星医药（集团）股份有限公司 依西美坦片及其制备工艺
KR100925811B1 (ko) * 2007-12-28 2009-11-06 주식회사 지에스메디칼 척추 고정기구
CN102939287B (zh) 2010-06-10 2016-01-27 塞拉根制药公司 雌激素受体调节剂及其用途
EP2616078B1 (en) 2010-09-16 2019-12-25 Shimoda Biotech (Pty) Ltd Fulvestrant compositions and methods of use
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
HUE063437T2 (hu) 2013-09-24 2024-01-28 Fujifilm Corp Nitrogént tartalmazó vegyületet vagy sóját vagy fémkomplexét tartalmazó gyógyászati készítmény
RU2729518C2 (ru) 2015-12-30 2020-08-07 Сент-Луис Юниверсити Мета-азациклические производные аминобензойной кислоты в качестве антагонистов пан-интегрина
TWI639430B (zh) * 2016-08-27 2018-11-01 中國醫藥大學 醫藥組合物用於製備治療胃癌藥物的用途
CN114948901B (zh) * 2022-05-06 2023-04-21 郑州大学第一附属医院 一种协同治疗乳腺癌的依西美坦纳米粒、制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
IL143901A0 (en) * 1998-12-23 2002-04-21 Searle & Co Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
GB9911582D0 (en) * 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
GB0005257D0 (en) * 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy

Also Published As

Publication number Publication date
US20040024044A1 (en) 2004-02-05
PE20020348A1 (es) 2002-04-18
MY137766A (en) 2009-03-31
NZ524104A (en) 2004-12-24
CN1729002A (zh) 2006-02-01
KR20030043955A (ko) 2003-06-02
WO2002020020A1 (en) 2002-03-14
JP2004508334A (ja) 2004-03-18
AU8986501A (en) 2002-03-22
AR034150A1 (es) 2004-02-04
MXPA03001983A (es) 2003-06-24
ZA200301309B (en) 2004-02-18
AU2001289865B2 (en) 2007-03-01
EP1317270A1 (en) 2003-06-11
CA2419590A1 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
BR0113625A (pt) Exemestano como agente de quimioprevenção
BR9915800A (pt) Produto terapêutico para supressão dos ruìdos de ronco
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
GB2394662A (en) Topical composition for treating pain
BR0113798A (pt) Derivados de resorcinol
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
MEP35308A (en) COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
UY26929A1 (es) Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis
CA2390295A1 (en) A method for chemoprevention of prostate cancer
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
BR0111729A (pt) 1-aril-4-oxo-1,4-dihidro-3-quinolinacarboxamidas como agentes antivirais
BR0312845A (pt) Tetratiomolibdato de tetrapropilamÈnio e compostos relacionados para terapias antiangiogênicas
BR0106687A (pt) Composição para intensificar a permeação de agentes tópicos à pele
BR0002921A (pt) Válvula solenóide
BRPI0505905A (pt) composição de limpeza para o clareamento da pele
AP2001002274A0 (en) Rescorcinol derivatives.
BR9916807A (pt) Antagonistas de 5ht1 para terapia antidepressiva
BR0115139A (pt) Compostos bis-heterocìclicos com atividade antitumor e quimiossensibilizante
BR0009194A (pt) Composição do resorcinol
ES2174297T3 (es) Nuevos derivados de piranosidos.
BR0111740A (pt) Terapia combinada contra tumores que compreende derivados de distamicina acriloila substituìda e agentes de alquilação
BR9814136A (pt) Conjunto contraceptivo, processos de fabricação do mesmo e de tratamento de sangramento, usos de anti-progestogênio, de progestogênio e de anti-progestogênio, e, de um composto.

Legal Events

Date Code Title Description
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S)8O, 10(VIII), 11, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.